Abstract library

27 results for "Castillo Mandon".
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#1165 Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients
Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (<20 mm). The current guideline bases the therapeutic recommendations on the pathologic size.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours
Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1384 Gastroenteropancreatic Neuroendocrine Tumors. Ten Year Experience at Instituto Oncologico Nacional. Panama 2004-2015.
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasm with a rising incidence worldwide.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD, MSc Omar Castillo-Fernandez
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#1399 High Grade Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). Instituto Oncologico Nacional. Panama City, Panama. 2004-2015
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare and complex neoplasms that present many clinical challenges. High grade at diagnosis is an adverse prognostic factor
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Joel Moreno-Ríos
#1422 Cystic Pancreatic Neuroendocrine Tumors: A Clinicopathologic Study and Long-term Follow-up after Surgical Resection in a Single Institution
Introduction: Cystic pancreatic endocrine tumors (CPETs) are rare lesions accounting for 2–17% of all endocrine pancreatic neoplasms. Their natural history and prognostic factors remain unclear
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: dr Anna Malpaga
Keywords: pancreas, cystic